9 February 2010

Kewill Systems

NO RECOMMENDATION

05/10/2001

Kewill's flagging share price received a much-needed boost on account of a positive trading update. Over the past 12 months the shares have slumped from a high of just over £10 to current levels, bottoming out at 30p in mid-September following a profit warning and the terrorist attacks on New York and Washington. The profit warning, which was delivered in August, saw supply-chain-management solutions business Kewill admit that sales in the first four months had been 'substantially below expectations' and that full year profitability was highly unlikely unless conditions dramatically improved. As a result of this statement broker forecasts were slashed. Market consensus had originally predicted that Kewill would continue to build on the success of last year, when pre-tax profits leapt 83% to £3.3m, with a profit in the region of £6.5m expected. Losses of around £5m are now being touted. Kewill's most recent update confirmed that first half figures are likely to be in line with these revised estimates, but stated that performance in the second quarter had shown a 'substantial improvement'. Although the dramatic improvement remains highly unlikely, management holds the belief that second half breakeven, at the operating level, is a distinct possibility.

Sector: Software & Computer Services

Companies: Kewill

Market cap: £32.1m

PE Forecast: n/a

Share price: 42p

Subscribe today

Growth Company Investor is the leading magazine for investors in AIM and boasts award-winning research and analysis coverage. 
Subscribe now and receive a 50% discount

AIM in Review 2010

Growth Company Investor, in association with the London Stock Exchange, presents the most wide-ranging and detailed examination of the AIM market: AIM in Review 2010. For more information and to order, click here or contact our marketing team on 020 7250 7056.

M&A on AIM 2009 - Which are the most active sectors for M&A? Which are the most active brokers to follow?

M&A on AIM 2009 is a unique and wide-ranging examination of merger and acquisition activity on AIM over the past 12 months, with an analysis of all the acquisitions, disposals, takeovers and delistings on AIM, including
canvassing the opinions of some of the major M&A powerbrokers. To order click here.

Free – Latest Stock Recommendations

Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.

Select your level of risk and we select the funds

Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.

The AIM Guide 2009/10

The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies.   Order your copy today and benefit from a £10 discount!

VCT Special Report 2009

This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.

Cash Shells Special Report 2009

Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.

Share recommendations and small-cap stock picks

Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.

Popular Recommendations

Latest Recommendations

Alliance Pharma 09/02/2010

Fast-growing Alliance Pharma is to buy most of Cambridge Laboratories' trade and assets for £14.3m and £16.4m.

May Gurney Integrated Services 09/02/2010

Investors seeking to back a business with exceptionally high earnings visibility and a burgeoning order book should look no further than Norwich-based infrastructure services specialist May Gurney.

Allocate Software 08/02/2010

Staff rostering software specialist Allocate, buoyed by 27% organic growth in the six months to November, aims to speed expansion with several acquisitions in coming years.

More Recommendations

Sectors

Vitesse Media Events